Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Artesun
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Details : OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Product Name : OT-101
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three time...
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : MGC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pulmoheal™/ Artiveda™ Is Clinically Active Against Mild and Moderate Covid-19
Details : PulmoHeal/ ArtiVeda has proven active against COVID-19 in ARTI-19 clinical trial (A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects w...
Product Name : PulmoHeal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19
Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.
Product Name : OT-101
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : Trabedersen,Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Oncotelic Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Manus Bio Awarded Additional Funding To Support Its Artemisinin Development Program
Details : Manus Bio has received a third funding award from the Bill & Melinda Gates Foundation to accelerate the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Artemisinin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta
Details :
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : $3.7 million
December 22, 2020
Lead Product(s) : Artemisinin,Boswellia Serata
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Malta Enerprises
Deal Size : $3.7 million
Deal Type : Funding
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : ArtemiC
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Artemisinin,Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 20, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Funding
Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries
Details :
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2020
Lead Product(s) : Artemisinin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Mateon Therapeutics
Deal Size : Undisclosed
Deal Type : Funding